Search
Promising Phase III Trial Results for Pfizer and Astellas' Drug Combination Therapy
2025-08-13 /
Read about 0 minute
Author：小编
Pfizer and Astellas Pharma have jointly announced remarkable outcomes from a Phase III clinical trial of their drug Padcev, administered in conjunction with Merck's Keytruda, for the treatment of bladder cancer. The combination therapy has exhibited significant improvements in both event-free survival and overall survival rates, setting a robust foundation for forthcoming regulatory submissions. This promising development underscores Pfizer's commitment to advancing its oncology treatment portfolio.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
